Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2571 to 2580 of 2607 total matches.
In Brief: Exenatide (Byetta) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $89; 2 years - $151;
3 years - $214. $44.50 ...
Patients may be asking about reports in the lay press that exenatide (Byetta - Med Lett Drugs Ther 2005; 47:45), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been used by diabetics and non-diabetics to lose weight. Approved by the FDA to improve glycemic control in patients with type 2 diabetes not controlled by metformin, a sulfonylurea or both, it is given by subcutaneous injection before the morning and evening meals. In clinical trials, some diabetic patients treated with the drug lost weight. No data are available on use in non-diabetics....
In Brief: Sodium Phosphate Colonoscopy Preps
The Medical Letter on Drugs and Therapeutics • May 22, 2006 (Issue 1235)
(US):
1 year - $89; 2 years - $151;
3 years - $214. $44.50 per year for
students, interns, residents ...
Last year, a Medical Letter article reviewing colonoscopy preparations warned that oral sodium phosphate preparations, such as Fleet Phospho-Soda solution and Visicol tablets, could cause significant electrolyte disturbances and, rarely, renal failure (Med Lett Drugs Ther 2005; 47:53). A subsequent report documented acute phosphate nephropathy and renal failure in 21 patients who had used sodium phosphate before colonoscopy (GS Markowitz et al. J Am Soc Nephrol 2005; 16:3389). Seventeen of these patients were women and 14 were taking an angiotensin-converting enzyme (ACE) inhibitor or...
Correction: Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007 (Issue 1276)
(US):
1 year - $89; 2 years - $151;
3 years - $214. $44.50 per year for
students, interns, residents ...
On page 100 of the article "Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures", under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of orthodontic rubber bands is not a highest-risk procedure that justifies prophylaxis; placement of orthodontic (metal) bands is. An orthodontic band is a metal ring that surrounds the tooth and is pressed into place causing movement in closely-spaced teeth and sometimes bleeding when the bands are placed close to the gumline.
In Brief: Meningococcal Prophylaxis
The Medical Letter on Drugs and Therapeutics • Apr 07, 2008 (Issue 1283)
to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $98; 2 years - $167;
3 years - $235. $49 per ...
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines (Med Lett Drugs Ther 2005; 47:29) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin (Cipro, and others) 500 mg has been used for prophylaxis after close...
Correction: A Sumatriptan Needle-Free Injection for Migraine
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010 (Issue 1342)
Subscriptions (US):
1 year - $98; 2 years - $167;
3 years - $235. $49.00 per year for
students, interns ...
In The Medical Letter article on Sumatriptan Needle-Free Injection for Migraine (2010; 52:50), on page 51, in Table 2, the injection volumes of Imitrex and Sumaval are listed as 5 mL. They should be 0.5 mL.
Is Accutane really dangerous?
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002 (Issue 1139)
: www.medicalletter.org
Subscriptions (U.S.)
1 year-$59; 2 years-$99; 3 years-$142
$29.50 per year for students ...
Isotretinoin (Accutane - Roche), an effective oral drug for treatment of acne, will soon be available generically. Concerns about its adverse effects, particularly psychiatric symptoms in adolescents, have been widely reported in the media.
Lp-PLA2: a New Marker of Vascular Risk
The Medical Letter on Drugs and Therapeutics • Oct 13, 2003 (Issue 1167)
-0500 Fax: 914-632-1733
Web Site: www.medicalletter.org
Subscriptions (U.S.)
1 year-$63; 2 years-$107 ...
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay, PLAC (diaDexus, Inc.), is now available to measure Lp-PLA2 levels. C-reactive protein (CRP), another inflammatory mediator, appears to be a biomarker for coronary disease (MH Shishehbor et al, Cleve Clin J Med 2003; 70:634). The role of Lp-PLA2 testing in determining cardiovascular risk is less clear.
Alpha-L-Iduronidase (Laronidase; Aldurazyme)
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
@medicalletter.org
Subscriptions (U.S.)
1 year-$63; 2 years-$107; 3 years-$151.
$31.50 per year for students ...
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost.
Seasonale
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004 (Issue 1175)
or
fax your request, or e-mail to permissions@medicalletter.org
Subscriptions (U.S.)
1 year-$63; 2 ...
Seasonale (Barr), the first "extended-cycle" oral contraceptive, is now available in the US for pregnancy prevention. Active tablets containing 30 ╡g of ethinyl estradiol and 0.15 mg of levonorgestrel are taken for 84 consecutive days, followed by 7 days of inactive tablets, allowing for withdrawal bleeding only four times a year. Other combination oral contraceptives are dispensed as 21 days of active tablets and 7 days of placebo or no tablets, resulting in 13 withdrawal bleeding episodes each year.
In Brief: Calcium and Vitamin D Supplements
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006 (Issue 1240)
-mail your request to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $89; 2 years - $151 ...
The results of a randomized, placebo-controlled trial of calcium and vitamin D supplements in more than 36,000 postmenopausal women, conducted as part of the Women’s Health Initiative (RD Jackson et al. N Engl J Med 2006; 354:669), have been misinterpreted by some patients to mean that they should stop taking such supplements.At the time of recruitment, the participants in this study had an average daily calcium intake of 1100-1200 mg. They were randomized to take either 1000 mg of calcium carbonate plus 400 IU of vitamin D3 or a placebo for an average of 7 years. Both groups were permitted...